## Haematologica HAEMATOL/2018/200253 Version 3

Long term follow-up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma

Enrico Maffini, Barry E Storer, Brenda M Sandmaier, Benedetto Bruno, Firoozeh Sahebi, Judith A Shizuru, Thomas R Chauncey, Parameswaran Hari, Thoralf Lange, Michael A Pulsipher, Peter A McSweeney, Leona Holmberg, Pamela S Becker, Damian J Green, Marco Mielcarek, David G Maloney, and Rainer Storb

Disclosures: Conflict-of-interest disclosure D.J.G. receives research support from Juno Therapeutics (Seattle, WA, U.S.A.). The remaining Authors declare no competing financial interests. Funding Research reported in this article was supported by the National Cancer Institute of the National Institutes of Health under award numbers CA078902, CA018029 and CA015704. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, which had no involvement in the in study design; the collection, analysis and interpretation of data; the writing of the report; nor in the decision to submit the article for publication.

Contributions: R.F.S, D.G.M. and E.M. conceived the study, E.M., R.F.S., B.B. and L.H. wrote the manuscript, B.E.S. performed the statistical analysis, L.H., M.M., D.J.G., B.M.S., D.G.M., B.B. assisted with study design, data interpretation and edited the manuscript, D.J.G. review clinical and biological risk stratification, F.S., J.A.S., B.B., T.L., E.D.A., P.A.M., M.A.P., P.H, T.R.C., B.M.S., D.G.M. provided study materials or patients and E.M., B.E.S., B.M.S., B.B., F.S., J.A.S., T.R.C., P.H., T.L. P.A.M., M.A.P., L.H.., P.S.B., D.J.G., M.M., D.G.M., R.F.S. approved the final manuscript.